Flora in ICUs has changed with the development of new therapies and the implementation of protocols regarding bacterial infections.
In this paper we propose a roadmap to support the development of new business models, their implementation and evaluation.
The success of genetic engineering, for both commercial and medical applications, will depend on a thorough understanding of gene regulation and the development of new technologies for their implementation.
The technique is known for over 20 years, but has recently received more attention due to the development of new materials for its implementation, but also because it seems ideally suited to specific product capture at large scale.
The collection of biospecimens is a critical component of the B2B Research Program that required the development of new procedures and the implementation of new technology.
The development of new antibiotics needs the implementation of innovative measures (cooperation between companies, private/public cooperation, increase in the duration of the patent of the drugs, financial reward, orphan drugs-like programs….).
Over the last decades, because of the joined efforts of European scientists, a significant progress in the understanding of epidemiology and pathophysiology of asthma and allergic diseases has been achieved, leading to the development of new prevention strategies and implementation of new treatment modalities.
In the last few years, the interest in the development of new pervasive or mobile implementations of air quality multisensor devices has significantly grown.
We aim to identify some of the major differences, outline the method of change in practice through the development of new joint protocols and determine implementation pathways.
Evidently, such heuristically designed experiments are not always maximally informative, a great impediment given the cost and effort involved in the development of new measurement techniques and the implementation of standard experiments.
Therefore, methods to estimate the non-neoplastic cell content of samples or tissue microdissection to standardize the proportion of neoplastic/non-neoplastic cells would be desirable in the development of new microarray-based classifiers and implementation of currently available gene expression signatures.
